Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.
BACKGROUND
Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are key players in stabilizing energetically-favored ligands, in an open conformational environment of protein structures. However, it is still poorly understood how the binding parameters associated with these interactions facilitate a drug-lead to recognize a specific target and improve drugs efficacy. To understand this, comprehensive analysis of hydrophobic interactions, hydrogen bonding and binding affinity have been analyzed at the interface of c-Src and c-Abl kinases and 4-amino substituted 1H-pyrazolo [3, 4-d] pyrimidine compounds.


METHODS
In-silico docking studies were performed, using Discovery Studio software modules LigandFit, CDOCKER and ZDOCK, to investigate the role of ligand binding affinity at the hydrophobic pocket of c-Src and c-Abl kinase. Hydrophobic and hydrogen bonding interactions of docked molecules were compared using LigPlot program. Furthermore, 3D-QSAR and MFA calculations were scrutinized to quantify the role of weak interactions in binding affinity and drug efficacy.


CONCLUSIONS
The in-silico method has enabled us to reveal that a multi-targeted small molecule binds with low affinity to its respective targets. But its binding affinity can be altered by integrating the conformationally favored functional groups at the active site of the ligand-target interface. Docking studies of 4-amino-substituted molecules at the bioactive cascade of the c-Src and c-Abl have concluded that 3D structural folding at the protein-ligand groove is also a hallmark for molecular recognition of multi-targeted compounds and for predicting their biological activity. The results presented here demonstrate that hydrogen bonding and optimized hydrophobic interactions both stabilize the ligands at the target site, and help alter binding affinity and drug efficacy.
Patil
Rohan
R
Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Maharashtra, India.
Das
Suranjana
S
Stanley
Ashley
A
Yadav
Lumbani
L
Sudhakar
Akulapalli
A
Varma
Ashok K
AK
D000595:Amino Acid Sequence; D000081247:CSK Tyrosine-Protein Kinase; D019295:Computational Biology; D015195:Drug Design; D006801:Humans; D006860:Hydrogen Bonding; D057927:Hydrophobic and Hydrophilic Interactions; D008024:Ligands; D008958:Models, Molecular; D008969:Molecular Sequence Data; D017433:Protein Structure, Secondary; D011505:Protein-Tyrosine Kinases / Q000737:chemistry / Q000378:metabolism; D016315:Proto-Oncogene Proteins c-abl / Q000737:chemistry / Q000378:metabolism; D011743:Pyrimidines / Q000737:chemistry / Q000378:metabolism; D019061:src-Family Kinases
D008024:Ligands; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; D016315:Proto-Oncogene Proteins c-abl; D019061:src-Family Kinases; C000631346:CSK protein, human
Acc Chem Res. 1996 Sep;29(9):441-9
23618410
Bioinformatics. 2007 Nov 1;23(21):2947-8
17846036
Methods Enzymol. 1991;202:512-43
1784187
Nature. 1993 Jun 3;363(6428):418-23
8502295
J Mol Graph Model. 2003 Jan;21(4):289-307
12479928
J Biol Chem. 2009 Sep 25;284(39):26797-802
19648119
J Med Chem. 1998 Mar 12;41(6):798-807
9526556
Indian J Biochem Biophys. 2004 Dec;41(6):273-80
22900354
PLoS Comput Biol. 2009 Mar;5(3):e1000335
19325869
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W590-4
15215457
Chem Biol Drug Des. 2010 Jan;75(1):3-17
19878193
Nature. 2004 Apr 1;428(6982):473
15057811
Curr Top Med Chem. 2006;6(14):1473-82
16918463
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9867-72
16788072
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2256-68
15572779
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
15299374
Proteins. 2007 Apr 1;67(1):128-141
17206656
Anal Biochem. 2008 Apr 1;375(1):60-70
18158907
J Phys Chem B. 2009 Sep 17;113(37):12615-21
19708644
Eur J Med Chem. 2008 Dec;43(12):2665-76
18342402
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6644-8
2204060
Proteins. 2001 Jan 1;42(1):108-24
11093265
Chem Commun (Camb). 2005 Jun 28;(24):2995-3001
15959566
Angew Chem Int Ed Engl. 1999 Mar 15;38(6):736-749
29711793
Nature. 1983 Jul 21-27;304(5923):273-5
6346109
Nature. 2006 Sep 7;443(7107):45-9
16915235
J Am Chem Soc. 1997 Jan 29;119(4):681-90
16526129
Oncogene. 2004 Oct 18;23(48):7906-9
15489908
Protein Eng. 2002 May;15(5):373-82
12034857
Trends Pharmacol Sci. 2005 Apr;26(4):178-82
15808341
Structure. 2009 Apr 15;17(4):489-98
19368882
Protein Eng. 1995 Feb;8(2):127-34
7630882
Anticancer Agents Med Chem. 2008 Feb;8(2):205-31
18288923
Drug Discov Today. 2008 May;13(9-10):433-9
18468561
Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44
14708008
Structure. 2004 Nov;12(11):1989-99
15530363
Cancer Res. 2007 May 1;67(9):4028-33
17483313
Med Chem. 2007 Nov;3(6):605-11
18045211
Bioinformatics. 2005 Feb 1;21(3):393-5
15347578
Expert Rev Mol Med. 2008 Mar 19;10:e8
18353193
Science. 1990 Apr 20;248(4953):358-61
2183354
Amino Acids. 2008 May;34(4):617-33
18180869
Org Biomol Chem. 2008 Oct 21;6(20):3703-13
18843400